학술논문

Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals
Document Type
Article
Author
Antonucci, GiorgioGirardi, EnricoCozzi-Lepri, AlessandroCapobianchi, Maria RosariaMorsica, GiuliaPizzaferri, PaoloLadisa, NicolettaSighinolfi, LauraChiodera, AlessandroSolmone, MariacarmelaLalle, EleonoraIppolito, GiuseppeMonforte, Antonella d'ArminioAncarani, FAntinori, AAntonucci, GBonasso, MBruno, RCapobianchi, MRCargnel, ACozzi-Lepri, Ad'Arminio Monforte, ALuca, A DeGalli, MGennero, LGirardi, ELipani, FMarino, NMilazzo, LMorsica, GNarciso, PPizzaferri, PPuoti, MSantantonio, TVerucchi, GMontroni, MScalise, GBraschi, MCPrete, MS DelTirelli, UCinelli, RPastore, GLadisa, NSuter, G Minafra. Bergamo: FArici, CChiodo, FColangeli, VFiorini, CCoronado, OCarosi, GCadeo, GPTorti, CMinardi, CBertelli, DRizzardini, GMigliorino, GManconi, PEPiano, PFerraro, TScerbo, APizzigallo, ED'Alessandro, MSantoro, DPusterla, LCarnevale, GGalloni, DViganò, PMena, MGhinelli, FSighinolfi, LLeoncini, FMazzotta, FPozzi, MCaputo, S LoAngarano, GGrisorio, BSaracino, AFerrara, SGrima, PTundo, PPagano, GCassola, GAlessandrini, APiscopo, RToti, MChigiotti, SSoscia, FTacconi, LOrani, APerini, PScasso, AVincenti, AChiodera, FCastelli, PScalzini, AFibbia, GMoroni, MLazzarin, ACargnel, AVigevani, GMCaggese, LMonforte, A d'ArminioRepetto, DNovati, RGalli, AMerli, SPastecchia, CMoioli, MCEsposito, RMussini, CAbrescia, NChirianni, AIzzo, CMPiazza, MMarco, M DeViglietti, RManzillo, EGraf, MColomba, AAbbadessa, VPrestileo, TMancuso, SFerrari, CPizzaferri, PFilice, GMinoli, LBruno, RNovati, SBaldelli, FTinca, MPetrelli, ECioppi, AAlberici, FRuggieri, AMenichetti, FMartinelli, CStefano, C DeGala, A LaBallardini, GBriganti, EMagnani, GUrsitti, MAArlotti, MOrtolani, PCauda, RDianzani, FIppolito, GAntinori, AAntonucci, GD'Elia, SNarciso, PPetrosillo, NVullo, VLuca, A DeGiambenedetti, S DiZaccarelli, MAcinapura, RLongis, P DeCiardi, MD'Offizi, GTrotta, MPNoto, PLichtner, MCapobianchi, MRGirardi, EPezzotti, PRezza, GMura, MSMannazzu, MResta, FLoso, KCaramello, PSinicco, ASoranzo, MLOrofino, GSciandra, MBonasso, MGrossi, PABasilico, CPoggio, ABottari, GRaise, EPasquinucci, SLalla, F DeTositti, GLepri, A Cozzi
Source
Antiviral Therapy; January 2005, Vol. 10 Issue: 1 p109-117, 9p
Subject
Language
ISSN
13596535
Abstract
The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined, The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive.A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation, Time to virological (achieving HIV RNA =500 copies/ml) and immunological success (a CD4+ count increase of =200cells/µl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model.Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success, After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34–0.93, P=0.03], Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects, These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.